Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 82.37% is 116% above its 5-year average of -523.28%, near the high end of its 5-year range (-3737.63%–668.95%).
16.30% above its 12-month average of 70.83%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 668.95%.
NET PROFIT MARGIN
82.37%
NET PROFIT MARGIN AVG TTM
70.83%
NET PROFIT MARGIN AVG 3Y
-212.25%
NET PROFIT MARGIN AVG 5Y
-523.28%
NET PROFIT MARGIN AVG 10Y
-171.31%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+16.30%
CURRENT VS 3Y AVG
+138.81%
CURRENT VS 5Y AVG
+115.74%
CURRENT VS 10Y AVG
+148.08%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
AnaptysBio, Inc.
Market Cap
$1.45B
Net Profit Margin
82.37%
TTM Avg
70.83%
3Y Avg
-212.25%
5Y Avg
-523.28%
Market Cap
$1.47B
Net Profit Margin
6.59%
TTM Avg
2.75%
3Y Avg
2.46%
5Y Avg
3.07%
Market Cap
$1.42B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.42B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.38B
Net Profit Margin
-10773.46%
TTM Avg
416506.27%
3Y Avg
203244.58%
5Y Avg
135206.06%
Market Cap
$1.53B
Net Profit Margin
12.02%
TTM Avg
-7.78%
3Y Avg
-15.24%
5Y Avg
-11964.64%
Market Cap
$1.53B
Net Profit Margin
80.56%
TTM Avg
35.15%
3Y Avg
48.19%
5Y Avg
54.54%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.45B | 82.37% | 70.83% | -212.25% | -523.28% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 6.59% | 2.75% | 2.46% | 3.07% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.42B | 0.00% | 0.00% | 0.00% | 0.00% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | 0.00% | 0.00% | 0.00% | 0.00% |
| GH Research PLC (GHRS)vs › | $1.51B | 0.00% | 0.00% | 0.00% | 0.00% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | -10773.46% | 416506.27% | 203244.58% | 135206.06% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.49B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.53B | 12.02% | -7.78% | -15.24% | -11964.64% |
| Innoviva, Inc. (INVA)vs › | $1.53B | 80.56% | 35.15% | 48.19% | 54.54% |
| Kardigan, Inc. (KARD)vs › | $1.36B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
20.4%
Net Profit Margin
82.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 668.95% |
| 2026-03-31 | -206.93% |
| 2025-12-31 | 45.83% |
| 2025-09-30 | 19.80% |
| 2025-06-30 | -173.52% |
| 2025-03-31 | -141.62% |
| 2024-12-31 | -50.53% |
| 2024-09-30 | -109.44% |
| 2024-06-30 | -425.30% |
| 2024-03-31 | -612.01% |
| 2023-12-31 | -468.75% |
| 2023-09-30 | -1124.41% |
| 2023-06-30 | -1151.59% |
| 2023-03-31 | -3220.89% |
| 2022-12-31 | -387.97% |
| 2022-09-30 | -2591.03% |
| 2022-06-30 | -2677.14% |
| 2022-03-31 | -3737.63% |
| 2021-12-31 | -3218.40% |
| 2021-09-30 | -31.91% |
| 2021-06-30 | -1.43% |
| 2021-03-31 | -161.49% |
| 2020-12-31 | 56.08% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | -55.08% |
| 2019-12-31 | -675.43% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -479.24% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | -319.16% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | -228.70% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | -38.34% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -154.65% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 39.69% |
| 2016-03-31 | -18.25% |
| 2015-12-31 | -86.63% |
| 2015-09-30 | -32.22% |
| 2015-06-30 | -1.13% |
| 2015-03-31 | -9.18% |
| 2014-12-31 | 13.55% |
| 2014-09-30 | 56.19% |
| 2014-06-30 | 18.22% |
| 2014-03-31 | -66.98% |
